Abstract : Given that clinical trials of poly ADP-ribose polymerase PARP 1 inhibitors are underway, in the present study we investigated the prevalence of triple-negative breast cancer and PARP1 expression in patients with primary invasive breast cancer. Immunohistological studies plus PARP staining were performed on samples from 206 primary breast cancer patients undergoing surgery at Showa University Hospital between January 2010 and May 2011. Fifteen patients 7.3 were found to have triple-negative breast cancer. Hormone receptor-positive patients were significantly more likely to be PARP1 negative. There were no PARP1-negative patients in the triple-negative group. However, there was no significant difference in the rate of PARP1 negativity between patients with triple-negative breast cancer and those with other breast cancer subtypes. There were no PARP1-negative patients in the triple-negative breast cancer group. Given that the effectiveness of PARP inhibitors has not been sufficiently established in clinical trials, a more in-depth analysis is required to determine the factors contributing to effective treatment. Future studies should include more subjects with triple-negative breast cancer and those with BRCA mutations.
Introduction
In the past, the classification of breast cancer was based largely on conventional histopathological diagnosis. Recently, a hierarchical clustering method based on gene expression profiling was shown to be useful for predicting treatment responsiveness and outcomes [1] [2] [3] . Using gene expression profiling, breast cancer can be classified into intrinsic subtypes through detailed gene expression analysis. In clinical practice, immunohistochemistry IHC can be a useful surrogate for the gene analysis used for tumor classification 4 . Patients are classified into the following groups on the basis of tumor characteristics : luminal A, consisting of patients who are positive for estrogen ER and /or progesterone PR receptors, but not human epidermal growth factor receptor 2 HER2 , and who have Ki67 levels ≥ 14 ; luminal B, consisting of patients who are ER and/or PR positive and either HER2 positive and / or with Ki67 levels ≥14 ;
HER2, consisting of patients who are HER-2 positive and ER and PR negative ; and triple negative, comprising patients who are negative for all three receptors ER, PR, and HER2 5 .
Currently, the treatment for breast cancer is largely decided on the basis of hormone receptor HR and HER2 status, with tumors classified into subtypes depending on the HR, HER2, and Ki67 status. This classification has an important role in determining both treatment and prognosis. For example, triple-negative breast cancer has a poor prognosis 6 and limited treatment options. Therefore, there is an urgent need to develop new drugs for the treatment of triple-negative breast cancer.
One of the characteristics of triple-negative breast cancer is that many of these tumors have DNA-repair defects in cells harboring BRCA mutations 7 . This has led to the development of poly ADP-ribose polymerase PARP inhibitors for the treatment of triple-negative breast cancer. PARP is an enzyme involved in the DNA repair process that was discovered independently by scientists in Japan and France approximately 40 years ago 8 9 . The main role of PARP is to detect and repair DNA single-strand breaks. Because tumor cells that are BRCA1 or BRCA2 deficient exhibit defective homologous combination repair of DNA double-strand breaks, it was expected that inhibition of PARP may destabilize the genome, leading to cell apoptosis Fig. 1 13 . Although clinical trials of PARP inhibitors are currently underway, the effectiveness of these agents has not been sufficiently established as yet.
The expression of the PARP1 in primary breast cancer has many questions. The aim of the present study was to investigate the prevalence of breast cancer subtypes in a Japanese cohort to establish their clinicopathological features, as well as PARP expression.
Materials and Methods
The subjects of the present study were 206 patients with primary invasive breast cancer who underwent surgery at Showa University Hospital between January 2010 and May 2011. Patients who were undergoing neoadjuvant therapies were excluded from the study. The clinicopathological variables evaluated were age, tumor size, histological type, nuclear grade NG , ER /PR, HER2, Ki67, lymphovascular invasion, and lymph node metastasis. Tissue specimens were stained immunohistochemically for PARP1 using antibodies obtained from Bethyl Laboratories location and an automated immunohistochemical assay Ventana HX company . After removal of paraffin, sections were washed and activated by heat treatment with EDTA. Endogenous peroxidase activity was inhibited by hydrogen peroxide solution, followed by blocking of non-specific protein binding. The primary antibodies were diluted 1 :250, and the secondary antibodies were conjugated with biotin IgG. Samples were visualized using avidin coupled with horseradish peroxidase, with diaminobenzidine as the chromogen, and enhanced by copper sulfate. Finally, samples were dehydrated, cleared, and mounted after nuclear staining with hematoxylin, as described previously 14 15 .
PAPR1 immunostaining was performed as described by von Minckwits et al 14 HER2 HR negative, HER2 positive ; or triple negative HR negative, HER2 negative . We also evaluated the clinicopathological features of the patients in each of these groups.
Statistical analysis
Data among the four groups were compared using Chi-squared analysis for independence 2 4 contingency table . Fisher s exact probability test was used to determine the significance of differences between two groups. Significance was set at P 0.05. 
Ethics approval
All patients provided informed consent for all investigations, including the retrieval of personal information from medical records.
Results
The mean age for all 206 patients was 58.1 years range 27 91 years , with a mean tumor size of 2.03 cm range 0.04 13.5 cm . Invasive breast cancer was identified histologically in 174 patients 84.5 , with the remaining 32 patients 15.5 having other types of breast cancer. Vascular invasion was found in 46 patients 22.3 . The NG was estimated to be Grade 1 in 99 patients 56. 9 cases, Grade 2 in 28 patients 16.1 , and Grade 3 in 47 patients 27.0 . Of the 206 patients in the study, 179 86. 9 were positive for HR and 27 13.1 were negative. HER2 was positive in 30 patients 14.6 and negative in 176 patients 85.4 . Lymph node metastases were present in 60 patients 29. 1 and absent in 164 patients 70.9 . Thirty-six patients were negative for PARP1 36 17.5 , whereas 45 21.8 , 53 25.7 , and 72 34. 9 patients exhibited weak, moderate, and strong PARP1 staining, respectively Table  1 . Examination of the associations between PARP1 expression and clinicopathological features revealed that significantly more HR-positive patients were PARP1 negative P 0.0008 PARP negative vs. weak staining ; P 0.0006 PARP negative vs. others . There were no significant differences for any of the other items evaluated Tables 2 3 . The prevalence of the luminal A, luminal B, HER2, and triple-negative breast cancer subtypes was 54. 4 n 112 , 32.5 n 67 , 5.8 n 12 , and 7.3 n 15 , respectively. The proportion of patients with each of these subtypes exhibiting negative, weak, moderate, and strong PARP1 expression is given in Table 4 . There were no significant differences in the distribution of PARP1 expression among the four groups, although it is of note that there were no PARP1-negative patients in the triple-negative breast cancer group Table 4 .
Discussion
Previous studies have reported that the prevalence of luminal A plus B, HER2, and triplenegative breast cancer subtypes is 60 80 , 10 15 , and 10 20 , respectively 18 19 .
In the present study, 86.8 of breast cancers were luminal, 5.8 were HER2 positive, and 7.3 were triple negative, indicating a higher proportion of patients with luminal breast cancer and a lower proportion of patients with triple-negative breast cancer. This is most likely due to the fact that we excluded patients undergoing neoadjuvant therapies from the present study. Generally, patients with HER2-positive or triple-negative breast cancer are more likely to be undergoing neoadjuvant chemotherapies than patients with luminal-type breast cancer.
PARP inhibitors are anticipated to be effective for triple-negative breast cancer because tumors harboring BRCA mutations have higher PARP activity 20 21 . However, we did not find any significant differences in PARP expression between patients with triple-negative breast cancer and other breast cancer subtypes in the present study, although there were no PARP1-negative patients in the triple-negative group. PARP1 negativity was significantly more common in the ER/PR-positive patients. One study as reported the absence of any correlation between PARP activity and PARP expression 22 . The results of the present study suggest that PARP inhibitors may be ineffective for HR-positive breast cancers with BRCA mutations. However, a Phase clinical trial of iniparib reported that the clinical benefit rate increased significantly from 34 to 56 P 0.01 when patients were treated with a combination of gemcitabine and carboplatin 23 .
However, the effectiveness of PARP inhibitors has not been sufficiently established in currently ongoing clinical trials 24 . A more in-depth analysis is required to determine the factors contributing to effective treatment. Then we advocate that the effectiveness of these agents be examined in patients.
There are several limitations to the present study. The main weaknesses of the immunohistochemical approaches used herein are their limited technical reproducibility, subjective interpretation, and qualitative readouts. Moreover, although we investigated PARP expression in the present study, we did not evaluate PARP activity.
Future studies into the expression of PARP1 as a biomarker for the therapeutic activity of PARP inhibitor-based therapy should include more subjects with triple-negative breast cancer, as well as those with BRCA mutations. 
